MedTrace Logo

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

NCT03818308 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-07-06

No results posted yet for this study

Summary

This is a single arm multicenter pilot study to evaluate the efficacy and safety of treatment with sofosbuvir (SOF)/velpatasvir (VEL) fix dose combination (FDC) in patients with acute hepatitis C virus (HCV) infection.

Conditions

  • Hepatitis C
  • Acute Hepatitis C

Interventions

DRUG

Sofosbuvir and Velpatasvir

All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.

Sponsors & Collaborators

  • HepNet Study House, German Liverfoundation

    collaborator NETWORK

  • Gilead Sciences

    collaborator INDUSTRY

  • German Center for Infection Research

    collaborator OTHER

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Markus Cornberg, Prof. Dr. · Hannover Medical School, Clinic for Gastroenterology, Hepatology, and Endocrinology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-28
Primary Completion
2021-06-08
Completion
2021-06-08

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03818308 on ClinicalTrials.gov